As of June 7, 2025, Incyte Corp (INCY) reports a EV/EBITDA of 45.50.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Incyte Corp's EV/EBITDA to Peers
To better understand Incyte Corp's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Incyte Corp (INCY) | 45.50 |
| TG Therapeutics Inc (TGTX) | 91.92 |
| Alkermes Plc (ALKS) | 11.39 |
| Halozyme Therapeutics Inc (HALO) | 10.69 |
| United Therapeutics Corp (UTHR) | 8.73 |
| Emergent BioSolutions Inc (EBS) | 8.32 |
Compared to its competitors, Incyte Corp's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.